Microbot Medical Q2 Revenue Surpasses Q1 as Accounts Double Post Full Release
Microbot Medical recorded its first-quarter 2026 revenue from a Limited Market Release and reports mid-Q2 revenue exceeding total Q1 results. Accounts more than doubled post-Full Market Release, with six states now using LIBERTY for procedures from robotic PAE to Y-90 liver radioembolization.
1. First-Quarter Revenue and Market Transition
Microbot Medical achieved its first recorded revenue in the quarter ended March 31, 2026, through a Limited Market Release of the LIBERTY Endovascular Robotic System. Early in Q2, mid-quarter sales have already outpaced the entire Q1, demonstrating accelerating adoption as the company shifts into Full Market Release.
2. Full Market Release and Account Expansion
Since launching the Full Market Release, the total number of hospital accounts has more than doubled. Hospitals in Georgia, Florida, New York, Michigan, Massachusetts and North Carolina now deploy the LIBERTY System, marking rapid geographic expansion across key U.S. territories.
3. Clinical Applications and Procedure Diversity
The LIBERTY System has been used for the world’s first robotic Prostatic Artery Embolization for BPH, robotic Genicular Artery Embolization for knee pain, and robotic Y-90 radioembolization mapping and treatment for liver cancer, among other endovascular procedures.
4. Growth Drivers and Commercial Outlook
Updated guidelines on occupational radiation and musculoskeletal protection, along with visibility at major conferences, are expected to accelerate U.S. adoption. A growing recurring order base, new accounts in the Midwest and Mid-Atlantic, and preparations for international rollout underpin the company’s expansion strategy.